Agree
Negatives include
1) 6 months of revenue (if it was approved)
2) The world ain't in a good state at the moment, if we have a correction, PE ratios will drop and investment in startups and reductions in share prices may well be amplified. Hopefully that wouldn't be the case for BOT
3) In the event of 2, valuation for a takeover could be less.
Just sayin!
Ann: FDA Letter Requires Patient Instruction Update, page-45
-
- There are more pages in this discussion • 251 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.030(8.70%) |
Mkt cap ! $570.1M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.5¢ | 31.5¢ | $6.354M | 19.19M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 286322 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 28500 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |